ArticleProbiotics and antimicrobial proteins2026
A Novel Bacteriocin from Insectivorous Bat (Hipposideros speoris) Intestine Mimicking Mammalian FAM216B: Probiotic, Antioxidant, and Antimicrobial Properties of Enterococcus hirae BNT6.
Article in Probiotics and antimicrobial proteins, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The alarming rise of antibiotic resistance necessitates the search for novel and safe alternatives to conventional therapies. Probiotics and their metabolites, particularly bacteriocins, are increasingly recognized for maintaining gut health, combating pathogens, and alleviating oxidative stress. Bats, with their diverse and underexplored gut microbiota, represent a unique reservoir of probiotic strains and bioactive peptides. This study aimed to isolate and characterize a novel probiotic strain from the intestine of the insectivorous bat Hipposideros speoris and evaluate its probiotic attributes, antioxidant potential, safety traits, and bacteriocin production. The isolated strain was identified as Enterococcus hirae BNT6 through 16S rRNA sequencing. Probiotic properties including acid and bile tolerance, cell surface hydrophobicity, adhesion to SW480 epithelial cells, and antioxidant activities (DPPH and ABTS scavenging) were assessed. Safety traits were evaluated through hemolysis, DNase activity, and antibiotic susceptibility testing. Bacteriocin purification was carried out using ammonium sulfate precipitation, gel filtration chromatography and RP-HPLC. Antimicrobial activity was tested against pathogenic bacteria, while molecular characterization was performed by SDS-PAGE, MALDI-TOF MS, peptide mass fingerprinting, spectroscopic analysis, and 3D in silico modeling. E. hirae BNT6 survived at pH 3, tolerated 0.3% bile salts, showed high hydrophobicity (51.7%), and adhered efficiently to SW480 cells. It exhibited strong antioxidant activity (65.7% DPPH and 81.6% ABTS scavenging). Safety evaluation confirmed its non-hemolytic, DNase-negative phenotype and susceptibility to most clinically relevant antibiotics. The purified bacteriocin, Enterocin BNT6, displayed broad-spectrum antimicrobial activity against Escherichia coli, Staphylococcus aureus, Listeria monocytogenes, and Bacillus subtilis, and remained stable under varying pH, temperature, and enzymatic conditions. Molecular analyses indicated a size of ~ 27 kDa (SDS-PAGE) and ~ 15 kDa (MALDI-TOF MS), with peptide mass fingerprinting showing 59% similarity to mammalian FAM216B protein. Structural studies revealed a predominantly α-helical conformation. Our findings establish Enterococcus hirae BNT6 as the first bat-derived probiotic strain producing a FAM216B-like bacteriocin with strong probiotic, antioxidant, and antimicrobial activities. In silico structural modeling revealed a predominantly α-helical, stable conformation with striking similarity to mammalian FAM216B, suggesting potential evolutionary mimicry. These unique attributes highlight its promise as a next-generation therapeutic and microbiome-based intervention.
Indexed as
Identifiers
41026409What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.